Search
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalAs of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma].
Etesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Atoltivimab (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions
Anethole
go.drugbank.com/drugs/DB15916ApprovedWithdrawnSynonyms: (E)-AnetholeCategories: Compounds used in a research, industrial, or household settingFenchone
go.drugbank.com/drugs/DB15918InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesTocopheryl nicotinate
go.drugbank.com/drugs/DB15921InvestigationalSynonyms: Vitamin E nicotinate, Vitamin E nicotinic acid esterCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingCarbaryl
go.drugbank.com/drugs/DB15930InvestigationalCategories: Compounds used in a research, industrial, or household settingImdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigationalImdevimab is a monoclonal antibody combined with [casirivimab] in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. … [L23539] This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.